
News|Articles|January 1, 2011
FDA Pipeline Preview, January 2011 (Ezogabine, Ticagrelor, Naltrexone SR/bupropion, Clostridium difficile vaccine, Elacytarabine, Glycerol phenylbutyrate, Perifosine, Cladribine Tablets, Florbetapir, ALS-AVP-21D9, Cyclosporine, PRX-8066, QLT091001)
Recent FDA action (through, December 2010) related to Ezogabine, Ticagrelor, Naltrexone SR/bupropion, Clostridium difficile vaccine, Elacytarabine, Glycerol phenylbutyrate, Perifosine, Cladribine Tablets, Florbetapir, ALS-AVP-21D9, Cyclosporine, PRX-8066, QLT091001.
Advertisement
Complete response
Recommended for approval
Fast-track designation
Orphan drug designations
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Health Begins at Home: Why Housing Has Become a Strategic Priority for Managed Care
2
CGM prescribed by primary care lowers A1C and acute care use in diabetes patients
3
A conversation with Dolores Malaspina, M.D., about the generational impact of Holocaust trauma on schizophrenia risk
4
Could uveitis in patients with melanoma being treated with immune checkpoint inhibitors be a good thing?
5


























